![Peter H. Reinisch](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter H.
Reinisch served as Director-Executive Board at Horizon Therapeutics Switzerland GmbH from 2009 to 2010.
He also worked as a Partner at Global Life Science Ventures AG.
Reinisch holds an undergraduate and doctorate degree from Vienna University of Economics & Business.
| Sociétés | Poste | Fin |
|---|---|---|
Global Life Science Ventures AG
 Global Life Science Ventures AG Investment ManagersFinance GLSV-Switzerland is an active, long-term manager which aims to create and build value exclusively in life science companies in the UK, Switzerland, German-speaking countries and the US which offer superior technologies and customer benefits. They invest in many areas of the life sciences including the cancer, immunology, vaccines, biopharmaceuticals, indication-specific genomics, genomics tools, diagnostics, medical devices, healthcare services and cardiovascular areas. The firm primarily invests in early-stage companies that operate in significant markets with considerable upside potential, as well as in later-stage companies, including buyouts, which meet their investment criteria. In their home markets, GLSV-Switzerland is the lead investor or an active co-investor, while outside of their home markets they only act as a knowledgeable co-investor. By investing in a syndicate, they offer investees access to the capital, experience and networks of international venture capitalists that invest in the life sciences on a global scale and who share the same investment criteria and philosophy. GLSV-Switzerland fosters openness, flexibility and dialogue on all issues relating to their investments and provides coaching, support, expertise and access to their network of scientific, industrial and financial professionals from prestigious institutions to their investee companies. The firm can invest up to 10% of their fund volume in an investee company. Depending on the stage of development of the company and the likelihood of further funding requirements, they generally invest €2-€5 million per company in each round of investment. | Private Equity Investor | 31/12/2014 |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Discovers and develops medicines for the treatment of chronic inflammatory diseases | Corporate Officer/Principal | 05/04/2010 |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 3 |
|---|---|
Vienna University of Economics & Business
 Vienna University of Economics & Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Horizon Therapeutics Switzerland GmbH
Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Discovers and develops medicines for the treatment of chronic inflammatory diseases | Health Technology |
Global Life Science Ventures AG
Global Life Science Ventures AG Investment ManagersFinance GLSV-Switzerland is an active, long-term manager which aims to create and build value exclusively in life science companies in the UK, Switzerland, German-speaking countries and the US which offer superior technologies and customer benefits. They invest in many areas of the life sciences including the cancer, immunology, vaccines, biopharmaceuticals, indication-specific genomics, genomics tools, diagnostics, medical devices, healthcare services and cardiovascular areas. The firm primarily invests in early-stage companies that operate in significant markets with considerable upside potential, as well as in later-stage companies, including buyouts, which meet their investment criteria. In their home markets, GLSV-Switzerland is the lead investor or an active co-investor, while outside of their home markets they only act as a knowledgeable co-investor. By investing in a syndicate, they offer investees access to the capital, experience and networks of international venture capitalists that invest in the life sciences on a global scale and who share the same investment criteria and philosophy. GLSV-Switzerland fosters openness, flexibility and dialogue on all issues relating to their investments and provides coaching, support, expertise and access to their network of scientific, industrial and financial professionals from prestigious institutions to their investee companies. The firm can invest up to 10% of their fund volume in an investee company. Depending on the stage of development of the company and the likelihood of further funding requirements, they generally invest €2-€5 million per company in each round of investment. | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
